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We have previously demonstrated that uPA is overexpressed in pancreatic tumors. In an attempt to diagnose these tumors earlier,
we sought to determine whether uPA could be identiﬁed in endoscopic retrograde cholangiopancreatography obtained brushings
inpatientswithmalignantpancreaticandbiliarystrictures.Secondarily,uPAwasmeasuredintheserumofthispatientpopulation.
uPA overexpression was identiﬁed in the cytologic tissue in 8 of 11 patients (72.7%). Serum analysis demonstrated a 2-fold higher
concentration of uPA in the pancreaticobiliary cancer patients (1.27 versus 0.56ng/mL; P = .0182). Also, uPA overexpression
correlated with serum levels (P<. 0001). This study conﬁrms that uPA can be detected in the ERCP cytologically obtained tissue
and is frequently present in a higher concentration in the serum of pancreaticobiliary cancer patients. A larger sample size will be
required to address its value as a sensitive marker for the diagnosis of pancreatic or biliary cancers.
Copyright © 2009 John F. Gibbs et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Pancreaticobiliary cancer remains a lethal disease where
treatment continues to be a major oncologic challenge. Most
patients present with advanced disease in which survival
is dismal. For patients diagnosed early with small tumors,
surgery oﬀers a chance of cure. In an attempt to diagnose
these tumors at an early stage, many studies have evaluated
the use of tumor markers, but so far, due to low sensitivity
and speciﬁcity, the results have not been promising [1].
Thehighmetastaticpotentialofpancreaticcancerhasled
researchers to investigate its ability to invade the basement
membrane and extracellular matrix (ECM) allowing it access
to capillaries and lymphatics. One process that has been
shown to be involved in invasion of most types of cancer
is the urokinase-type plasminogen activator system [2]. uPA
is a serine proteinase that is best known for catalyzing the
conversion of inactive plasminogen to the active proteinase
plasmin. uPA and its receptor uPAR have been demonstrated
to be involved in tumor invasion, growth, and metastasis.
Independently or through the activation of plasmin, uPA can
degrade ECM, activate matrix metalloproteinases, mediate
the release of growth factors (including transforming growth
factorβ,ﬁbroblastgrowthfactor,vascularendothelialgrowth
factor, insulin growth factor, tumor necrosis factor α,a n d
hepatocyte growth factor), stimulate cellular migration,
induce chemotaxis, and promote angiogenesis [3, 4].
Sincethe1980swhenuPAwaspostulatedtohavearolein
tumor invasion, there have been multiple studies evaluating
it as a prognostic marker of cancer. It was ﬁrst studied in
breast cancer where it has been shown as an independent
prognostic marker for predicting survival second only to
lymph node status [5]. Following the initial results in
breast cancer, uPA overexpression was shown to confer a
worse prognosis in many other cancers including colorectal,
esophageal, gastric, hepatocellular, prostate, sarcoma, and
head and neck squamous cells among others [6–12].
The importance of the uPA activator system has also
been demonstrated in pancreatic cancer [13–18]. The ﬁrst
study to show overexpression of uPA in pancreatic cancer2 HPB Surgery
was by Takeuchi et al. in 1993. He demonstrated by
immunohistochemical staining that 78% of pancreatic can-
cers overexpressed uPA and this overexpression correlated
with decreased survival [13]. Another study by Cantero et al.
in 1997 showed that concomitant overexpression of uPA and
its receptor uPAR correlated with shorter survival times [14].
We detected uPA overexpression in pancreatic intraepithelial
neoplasia (PanIN) and histologically normal ducts/acini that
are in the immediate vicinity of the tumor. uPA was also
foundinthevesselsoftumorstromasuggestingthatuPAisin
circulation[15],andthereforeshouldbedetectablebyserum
analysis.
One method of diagnosing pancreaticobiliary tumors is
endoscopic retrograde cholangiopancreatography (ERCP).
It allows further evaluation through imaging of the ductal
system and allows to sample pancreatic juice and brush
biopsy cytology for further analysis [19]. ERCP has also been
studied in small numbers to screen high-risk patients with
a family history of pancreatic cancer, and it demonstrated
that cytologic brushings showing dysplasia correlate with
the pathologic specimen after resection [20, 21]. Despite
combination of sampling with brush cytology, ﬁne needle
aspiration, and biopsy, the sensitivity of all three combined
is only 62%. Most practitioners perform only brush cytology
which by itself has a sensitivity of only 30% in the diagnosis
of pancreaticobiliary malignancies.
We hypothesized that molecular markers such as uPA
may improve our ability to diﬀerentiate malignant from
benign pancreaticobiliary strictures and assist us in planning
therapeutic strategies. We performed a feasibility study
of patients undergoing ERCP for conﬁrmed or suspected
pancreaticobiliary cancers to determine whether uPA over-
expression could be identiﬁed from cytologic brushings.
Serum levels of uPA were measured in this patient group and
compared to healthy subjects.
2. Patientsand Methods
2.1. Patients. IRB approvals at University of Buﬀalo and
Roswell Park Cancer Institute were obtained. Eleven patients
with known or suspected pancreaticobiliary malignant stric-
tures secondary to either pancreatic cancer or cholangiocar-
cinoma as determined clinically by radiologic studies were
consentedtohavecytologicbrushingsobtainedduringERCP
for evaluation of expression of uPA. At ERCP, cytologic
brushings of the common bile duct or pancreatic duct
were performed. Brushings were obtained in duplicate. The
samples were ﬁxed in 70% ethanol and stored in Phosphate
buﬀered saline. One slide was routinely stained for H&E to
identify the presence of epithelial cells and the other was
stained for uPA in a blinded fashion. Presence and type
of cancer were determined by biopsy and reviewed by a
pathologist. Serum samples were drawn from these patients.
Eleven normal healthy subjects consented to have serum
samples drawn for measurement of uPA.
2.2. Antibody and Reagents. uPA1 monoclonal antibody
directed toward the catalytic domain of the uPA β-chain,
no. 3689, was obtained from American Diagnostica Inc.
(Greenwich, CT). The speciﬁcs of the antibody have previ-
ously been described [10]. uPA1 (no. 3689) is strictly active-
site speciﬁc. Reagents used in the immunohistochemical
procedure including blocking solution, secondary antibody,
and Vectastain Elite ABC reagent were purchased as the
R.T.U Vectastain Universal Elite ABC kit (Vector Labora-
tories, Burlingame, CA). Color-development reagents were
purchased as part of a DAB substrate kit for peroxidase
(Vector Laboratories, Burlingame, CA). The DAB substrate
kit contained the reagents required to make a working
solution of 3,3 -diaminobenzidine (DAB) for staining tissue
sections. Triton X-100 was purchased from Sigma (St. Louis,
Mo, USA).
2.3. Immunohistochemistry. uPA expression in cytologic
brushings obtained during ERCP was evaluated by immuno-
histochemistry (IHC). Cells from the brushings were ﬁxed
onto slides. Details of the IHC procedure have been previ-
ously described [15]. The uPA1 primary antibody was used
at a concentration of 20μg/mL. Cells were blocked with
normal horse serum (2.5%) for one hour and incubated
overnight at 4◦ Celsius with the primary antibody. After
gently rinsing the cells with Triton-TBS, they were treated
with the secondary antibody (R.T.U. Biotinylated Universal
Antibody and Anti-Rabbit/Anti-Mouse IgG made in horse),
gently washed and treated with Vectastain Elite ABC reagent.
Color development was performed using a DAB substrate
kit for peroxidase. The slides were then counterstained with
hematoxylin and mounted with a coverslip. Normal kidney
sections were used as positive controls for uPA. A slide of
cytologic brushings was also stained by the same procedure,
except that an irrelevant isotype IgG was substituted for the
primary antibody as a negative control. Staining intensity for
uPAwasclassiﬁedas0–3+(0absent;1+,weak;2+,moderate;
3+, strong).
2.4. ELISA. Serum levels of uPA were analyzed using an
enzyme-linked immunosorbent assay (ELISA). ELISA kits
are available commercially to perform these assays. uPA
ELISA kits were purchased from American Diagnostica, Inc.
(Greenwich, CT). The assays and data calculations were
performed according to the manufacturer’s instructions.
2.5. Statistical Analysis. Diﬀerences between groups were
analyzed by an exact Wilcoxon rank-sum test. Correlation
between IHC grade and serum levels of uPA was estimated
with the Spearman rank correlation coeﬃcient. The exact
permutation P value computed for testing the correlation is
zero versus not. All tests were two sided and tested at level
alpha = 0.05. Descriptive statistics were given as mean and
standard deviations (SD). All tests were carried forth using
SAS 9.2, SAS Institute Inc., Cary, NC.
Givenn = 11subjectspergroupandassumingexchange-
ability under the null hypothesis, the Wilcoxon rank-sum
test would be able to detect approximate shift alternatives
of roughly 0.6ng/mL, 1.3ng/mL, and 1.7ng/mL given 0.80
power and common standard deviations under the null
hypothesis of no diﬀerence of 0.5ng/mL, 1.0ng/mL, and
1.9ng/mL, respectively.HPB Surgery 3
Table 1: Clinical and pathologic characteristics of patients with pancreaticobiliary malignancy. IHC staining grade for uPA and serum uPA
values for 6 of 8 patients with pancreatic adenocarcinoma and 2 of 3 patients with cholangiocarcinoma overexpressed uPA on cytology
obtained from ERCP brushings. Serum values correlated to intensity of staining.
Patient Sex Age (yrs) Cancer Type Tumor Size CA 19-9 (U/mL) IHC Grade Serum uPA (ng/mL)
1 M 57 Pancreatic 3cm 27.8 2+ 1.18
2 M 35 Pancreatic 4.5cm 348 3+ 0.84
3 F 73 Pancreatic 5.2cm 45.7 3+ 5.86
4 M 71 Pancreatic 3.3cm 450 2+ 0.87
5 M 60 Pancreatic 3cm 83.9 2+ 0.2
6 M 39 Pancreatic 5cm 126 2+ 0.61
7 F 78 Pancreatic 3.0 <1.0 0 0.61
8 F 56 Pancreatic 4cm 138 0 0.53
9 F 78 Cholangiocarcinoma 1.2 42 3+ 0.98
10 M 82 Cholangiocarcinoma 1.0 830.3 2+ 0.73
11 M 78 Cholangiocarcinoma 2cm 52.3 0 0.52
3. Results
The clinical and pathologic characteristics of patients are
summarized in Table 1. There were 8 men and 3 women.
TheMedianagewas61years(35–82yrs).Adequatecytologic
brushings were obtained in all 11 patients. On ﬁnal pathol-
ogy, 8 patients had pancreatic adenocarcinoma and 3 had
cholangiocarcinoma. When immunohistochemistry for uPA
was performed on the cytology specimens, six of the eight
patients (75%) with pancreatic cancer (Figure 1) and two of
the3patients(67%)withcholangiocarcinomaoverexpressed
uPA (Figure 2). The two patients with pancreatic cancer who
did not overexpress uPA were being treated with chemother-
apy and underwent ERCP for biliary stent exchange. The
remaining patients were all chemotherapy na¨ ıve at the time
of biliary decompression.
The mean serum uPA in the 11 patients with cancer
was 1.27ng/mL (SD = 1.54). The mean serum uPA in the
11 normal healthy individuals was 0.56ng/mL (SD = 0.16).
Serum analysis demonstrated a 2-fold higher concentration
of uPA in the pancreaticobiliary cancer patients compared to
the healthy controls (P = .0182). Table 1 compares the level
ofuPAstainingincytologicspecimenstoserumlevelsofuPA
for all 11 patients.
The IHC grade for uPA staining correlated with serum
levels for uPA (r = 0.72; P<. 0001).
4. Discussion
A deﬁnitive diagnosis of cancer can be diﬃcult in patients
with pancreaticobiliary strictures with no obvious mass on
imaging studies. Furthermore patients with an indistinct
small pancreatic mass or chronic pancreatitis provide diag-
nostic dilemmas. Current tumor markers such as CA19-9
and CEA are often not useful. We have previously shown
that uPA is an early event in the malignant transformation
of pancreatic cancer [15]. Therefore we sought to determine
the feasibility of determining uPA expression in cytologic
brushings of established malignant strictures to evaluate its
Figure 1: Immunohistochemistry using uPA antibody. Cytologi-
cally malignant cells stained positive for uPA cells from cytologic
brushings obtained from a pancreatic adenocarcinoma patient
during ERCP (arrows).
Figure 2: Immunohistochemistry using uPA antibody. Positive
staining of cholangiocarcinoma cells from cytologic brushings
obtained during ERCP (arrows).
potential as an adjunct to ERCP in diagnosis of pancreatico-
biliary malignancies.
In our small sample, we found it is possible to identify
overexpression of uPA in cells obtained from brushings
during ERCP. uPA overexpression (72.7%) appears to
be a marker for pancreatic or biliary cancers. Six out of4 HPB Surgery
8 (75%) pancreatic cancer patients overexpressed uPA.
The two patients who did not were being treated with
chemotherapy. Although there is no current literature to
show that chemotherapy directly inhibits uPA synthesis, we
have postulated that this treatment impedes growth, and
thus decreases uPA expression. The relationship between
uPA overexpression and cholangiocarcinoma has not
been studied, but in two of the three (66%) samples, the
immunohistochemical analysis of the cytologic brushings
showed overexpression. As ERCP is an invasive technique
with potential morbidity, we also looked at serum uPA in
our patient population, and it was elevated in patients with
pancreaticobiliary cancer. The serum levels correlated with
the IHC grade of uPA in tissue (P<. 001). Serum uPA
levels have been evaluated in breast cancer by Rha et al.,
who showed blood uPA levels correlated with those of tissue
[22]. Because our study contains only a small number of
patients, the value of serum uPA as a tumor marker needs to
be further evaluated in large numbers of patients including
patients with chronic pancreatitis before it can be compared
to the standard tumor markers such as CA19-9.
Currently there are no established screening tests for
pancreatic cancer. The United States Preventive Services
Task Force (USPSTF) has recommended against routine
screening for pancreatic cancer based upon the lack of
data demonstrating its clinical value in the general pop-
ulation [23]. Familial pancreatic cancer (FPC) accounts
for up to 10% of patients with pancreatic cancer [24].
The precursor lesion to pancreatic cancer is pancreatic
intraepithelial neoplasia (PanIN). PanIN is graded from
I–III, and patients with PanIN III have been considered
f o rp a n c r e a t e c t o m yb ys o m eg r o u p s[ 25]. Surveillance by
ERCPandendoscopicultrasoundisperformedinanattempt
to identify patients with FPC who have developed PanIN,
but the diagnosis is diﬃcult [26]. We have demonstrated
that uPA is overexpressed in 30%–70% of patients with
PanIN [15]. Evaluating uPA overexpression from ERCP
obtained cytologic brushings may have potential application
in screening high-risk patients by identifying either PanIN or
invasive pancreatic cancer.
Although ERCP arguably remains the golden standard
for pancreaticobiliary evaluation, there is a risk of compli-
cations associated with ERCP including pancreatitis (5.4%)
[27]. Endoscopic ultrasound (EUS) with EUS-guided FNA
has emerged as an extremely sensitive and speciﬁc method
of diagnosing pancreatic cancer and can detect small lesions
more eﬀectively than conventional imaging. For the diagno-
sis of pancreatic cancer, the sensitivity has been reported to
range from 75%–90% and speciﬁcity from 82%–100% [28].
As we have shown that uPA staining can be performed on
b r u s hc yt o l o gy ,i tc a nb ed o n eo nF N As p e c i m e n sa sw e l la n d
may improve diagnostic accuracy.
As targeted therapy has stepped to the forefront of
cancer research, molecular markers have moved from their
traditional roles of diagnosis and staged to possible aims of
treatment. Already uPA has been evaluated as a potential
target for treatment to decrease the invasive and metastatic
activity of pancreatic tumor cells. Bauer et al. evaluated an
anti-uPAR monoclonal antibody in mice and found that
it signiﬁcantly decreased tumor growth, hepatic metastases,
and retroperitoneal invasion [29]. Small molecule inhibitors
of uPA have been evaluated in a ﬁbrosarcoma model in mice
resulting in decreased metastases and prolonged survival
[30]. These results suggest that detecting overexpression of
uPA in pancreatic cancers may not only be prognostic and
diagnostic but may also direct treatment in the future.
A serious limitation of the current study is its small
samplesizeandlackofanadequatecontrolgroupprecluding
meaningful analysis. In this study, a control group of healthy
subjects for the analysis of uPA in the serum was obtained.
There are obvious ethical issues in obtaining brushing from
healthy volunteers and it would appear more suitable to
utilize patients with benign pancreatic and biliary strictures.
We elected to exclude potential control groups such as
those presenting with obstructive jaundice from benign
pancreaticobiliary strictures. The possibility that some of
these patients harbored occult malignancy would be diﬃcult
to discern without long term follow up. Even in patients
with choledocholithiasis, there may be a potential for the
associated inﬂammatory process to elevate uPA levels. Thus,
we performed this feasibility study in patients with known or
suspected pancreaticobiliary malignancies by brush cytology
to corroborate our prior ﬁndings in resected pancreatic
cancer specimens.
5. Conclusion
We performed a feasibility study to determine whether
uPA overexpression could be identiﬁed from cytologic
brushings of patients undergoing ERCP for conﬁrmed or
suspected pancreaticobiliary cancers. Serum levels of uPA
were measured in this patient group and correlated with uPA
overexpression. Larger studies involving all forms of pan-
creaticobiliary pathology need to be performed before uPA
overexpression can be used either as a serum or a cytological
tumor marker, especially those with no identiﬁable masses.
Also comparison with other tumor markers, that is, CA 19-9
and CEA will be required to substantiate the role of uPA as a
diagnostic or prognostic tumor marker.
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